L A M Y Stock Price, News & Analysis

L A M Y (LMMY), also referenced in recent disclosures and news as LAMY Inc. and LAMY, is an SEC-reporting company that has undergone a significant strategic shift through the acquisition of Exousia AI, Inc. According to its Form 8-K and related press releases, the company is transitioning from an education-focused technology model toward operating as a clinical-stage biotechnology enterprise centered on exosome-based therapies, particularly in oncology.

Following the closing of a Plan and Agreement of Reorganization, Exousia AI became a wholly owned subsidiary of L A M Y, and the company’s board adopted Exousia AI’s business plan as part of its overall strategy. In the 8-K, Exousia AI is described as a clinical stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of cancer treatment. The business summary notes a proprietary manufacturing process that utilizes plant-based materials to create exosomes and a proprietary loading technology capable of infusing a range of molecules, from drugs to DNA.

Exosome-Based Biotechnology Focus

The company’s exosome strategy, as set out in the 8-K description of Exousia AI, is organized into three planned divisions:

• Biotech: Developing new therapies using exosomes, with a focus on cancer.
• Cosmeceutical: Applying plant-based exosomes in skincare-related uses, including ongoing studies involving skincare treatments.
• Nutraceutical: Working on adding exosomes to certain anti-aging supplements, IV therapies, tinctures, and peptides.

The 8-K further explains that plant-based exosomes, sometimes called plant-derived extracellular vesicles, are small membrane-bound structures secreted by plant cells that can carry proteins, lipids, RNA, and other biomolecules. The filing describes how these vesicles are being explored for potential roles in drug delivery, health-related applications, and other areas due to their bioactive components and perceived sustainability characteristics.

Plant-Based Exosomes and Potential Applications

In its regulatory disclosure, the company outlines several potential applications for plant-based exosomes as it sees them. These include possible health-related benefits, exploration as drug delivery systems, and interest in their use in areas such as immunotherapy and vaccine development. The 8-K discusses the idea that plant exosomes may be used to carry therapeutic agents, RNA molecules, or other cargo to specific tissues or cells, and notes ongoing research interest in their use for targeted delivery, disease management, and nutraceutical concepts.

The company’s narrative in the 8-K emphasizes that it is developing plant-based exosome products with the goal of loading these vesicles with various biomimetic factors, including growth factors, peptides, liposomes, amino acids, and proteins, with a view toward targeting inflammation, wound-related processes, and other biological pathways. The filing also describes exosomes more generally as small vesicles involved in intercellular communication, sometimes likened to a courier system for molecular cargo.

Transition from EdTech and Financial Education

Earlier news releases describe LAMY Inc. as an edtech and gaming-focused company dedicated to children’s financial education through gamified and immersive e-learning experiences. These releases highlight a flagship platform called TwoPlus1®, characterized as a video game and metaverse-style financial education ecosystem that integrates technologies such as artificial intelligence, blockchain, and real-time financial simulation. The platform is presented as teaching financial knowledge and resource management to children through virtual economies, including virtual asset trading and real estate simulations, with revenue models based on subscription fees, virtual asset transaction commissions, and advertising.

Press releases also describe initiatives such as a GenZ financial literacy program built around user-generated content and creator tools within TwoPlus1®, partnerships involving green energy NFTs and metaverse-based energy storage demonstrations, and collaborations to integrate art, cultural heritage, and NFTs into the educational ecosystem. These activities reflect the company’s prior positioning in the education and training services space, particularly around gamified financial literacy.

However, the Form 8-K dated in November 2025 makes clear that the board has adopted Exousia AI’s biotechnology business plan as part of the company’s overall plan, and subsequent news refers to LAMY "to become Exousia Bio, Inc." and operating as a U.S. biotechnology company focused on exosome-based cancer therapy. This indicates a corporate realignment toward biotechnology and exosome-based therapeutics, while legacy descriptions provide historical context about its edtech origins.

Relationship with Exousia Pro and Licensing Structure

Separate news coverage describes a broader corporate structure involving Exousia Pro, Inc. (traded under a different symbol) and its subsidiaries. Exousia Pro is characterized in those releases as a clinical-stage biotechnology company developing mammalian and plant-derived exosomes using proprietary nucleic acid loading and targeted delivery technologies. One release explains that Exousia Pro completed a transaction in which it acquired a controlling interest in LAMY by exchanging its subsidiary Exousia AI for restricted shares of LMMY, positioning Exousia Pro as the controlling shareholder of L A M Y.

That same news item notes that Exousia Pro entered into a licensing agreement with LAMY, providing for annual licensing fees and ongoing royalties based on the future commercial success of technology to be exploited by LAMY through Exousia AI. It also describes LAMY as an audited SEC-reporting platform that can support capital-raising and valuation of exosome-related intellectual property, including glioblastoma and cancer treatment assets.

Exousia Bio Branding and Oncology Focus

Subsequent press releases refer to LAMY, to become Exousia Bio, Inc., operating under the shorthand "Exo Bio" and describe it as a U.S. biotechnology company focused on exosome-based cancer therapy. These releases state that Exousia Bio develops and manufactures mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The described platform is said to enable custom production of exosomes with enhanced genetic functionality, with the aim of selectively targeting specific cells to address diseases with significant unmet medical needs.

According to these news items, the company’s engineered exosomes have demonstrated potential to target cancer stem cells, which are described as primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. The same platform is also described as having potential relevance for a range of viral infections. One press release highlights a completed in-vivo mouse study using exosomes to treat glioblastoma multiforme and notes that the results are being prepared for peer-reviewed publication.

Another news release notes that Exousia AI has received an Orphan Drug Designation from the U.S. Food and Drug Administration for a glioblastoma therapy, and that this designation is viewed by the company as an important regulatory milestone associated with the exosome-based oncology platform. The acquisition of Exousia AI by LAMY is presented as consolidating ownership of this preclinical oncology platform and related intellectual property.

Licensing and Intellectual Property Around Diagnostics and Therapy

In a related development, a separate company, Exousia Pro, Inc., announced an exclusive licensing agreement with the University of Central Florida (UCF) for technology involving exosome-based cancer diagnostics and therapy platforms. The news release describes intellectual property around Exosomal NANOG DNA as a diagnostic cancer marker and an exosomal delivery platform for gene expression-modulating agents targeting cancer and viral infections. It also notes that Exousia Pro plans to grant a sub-license to LAMY, to become Exousia Bio, Inc., for cancer-therapy applications.

Within that context, the licensed technology is described as supporting development of a NANOG DNA cancer screening test, characterized in the release as a non-invasive, saliva-based diagnostic concept using PCR processing. While this licensing announcement is issued by Exousia Pro rather than LAMY itself, it explicitly references a planned sub-license to LAMY/Exousia Bio for therapeutic applications, indicating that LMMY’s future biotechnology activities may be tied to these exosome-based diagnostic and therapeutic platforms as described in the news.

Regulatory Status and Reporting

L A M Y is identified in SEC filings as a Wyoming corporation and an emerging growth company. The Form 8-K specifies that the company’s securities are not listed on a national securities exchange and that it has no securities registered under Section 12(b) of the Exchange Act, while news releases reference trading on OTC markets under the symbol LMMY. A separate Form 12b-25 (NT 10-Q) filing explains that the company experienced delays in completing financial statements, auditor review, and management’s discussion and analysis for a quarterly report, and indicates that it expected to file the Form 10-Q within the extension period allowed by the rule.

Across these disclosures and news items, L A M Y (LMMY) is presented as an SEC-reporting, emerging growth company that has shifted its core business plan toward exosome-based biotechnology through the acquisition of Exousia AI, with historical ties to gamified financial education and a branded TwoPlus1® platform. Investors and observers reviewing this overview can use it as a consolidated reference to the company’s stated biotechnology focus, exosome strategy, licensing relationships, and prior edtech activities as described in the available filings and press releases.